Lifecore Biomedical, Inc. \de\ (LFCR) · Oct 20, 2026 · Acquisition
Special meeting process — November 4, 2026 record date
Lifecore’s merger process moves toward a shareholder vote, but this 8-K adds timing mechanics—not new deal economics or approval.
Lifecore is a sterile-injectables contract development and manufacturing organization that is being taken private by Webster Equity Partners under the merger announced September 27, 2026. This filing advances the deal administratively, not economically. The board set November 4, 2026 as the stockholder record date for the special meeting. 〔0〕 That determines which holders can vote; it does not itself approve the transaction, set a meeting date, change the merger consideration, or confirm closing.
The next meaningful step is proxy disclosure. Lifecore says it will file a preliminary proxy statement and intends to file a definitive proxy statement, which will provide the detailed information stockholders need before voting. 〔1〕 Because the merger itself was already publicly announced, this notice is confirmation of an expected process milestone rather than a fresh deal surprise.
Bottom line: The merger is moving through the expected shareholder-approval process, but this 8-K does not materially change the deal or Lifecore’s underlying business story. It matters as a procedural step, not as new transaction information.
Preliminary proxy statement filing
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!